FY2025 EPS Estimates for Lantheus Cut by Leerink Partnrs

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Lantheus in a research report issued on Wednesday, November 12th. Leerink Partnrs analyst R. Ruiz now expects that the medical equipment provider will post earnings per share of $4.55 for the year, down from their previous estimate of $4.84. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ Q4 2025 earnings at $0.89 EPS and FY2026 earnings at $4.88 EPS.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million for the quarter.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. JMP Securities lowered their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Mizuho cut their price target on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Finally, TD Cowen dropped their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $74.17.

Lantheus Trading Down 1.0%

Lantheus stock opened at $52.50 on Monday. The firm’s 50-day moving average is $53.88 and its 200-day moving average is $66.12. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.29. The company has a market cap of $3.48 billion, a P/E ratio of 13.96 and a beta of 0.04.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Lantheus in the third quarter worth approximately $7,023,000. XTX Topco Ltd raised its stake in shares of Lantheus by 16.8% in the 3rd quarter. XTX Topco Ltd now owns 11,188 shares of the medical equipment provider’s stock worth $574,000 after buying an additional 1,611 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in shares of Lantheus in the 3rd quarter worth $3,772,000. Verition Fund Management LLC lifted its holdings in shares of Lantheus by 419.3% in the third quarter. Verition Fund Management LLC now owns 162,970 shares of the medical equipment provider’s stock valued at $8,359,000 after buying an additional 131,585 shares during the period. Finally, Vestal Point Capital LP boosted its stake in Lantheus by 240.0% during the third quarter. Vestal Point Capital LP now owns 170,000 shares of the medical equipment provider’s stock valued at $8,719,000 after buying an additional 120,000 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.